, Tracking Stock Market Picks
Enter Symbol:
Immunomedics, Inc. (IMMU) [hlAlert]

down 49.09 %

Immunomedics, Inc. (IMMU) rated Outperform with price target $8 by Oppenheimer

Posted on: Wednesday,  Oct 2, 2013  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Immunomedics, Inc. (NASDAQ: IMMU) on 10/02/2013. Previously Oppenheimer rated Outperform Immunomedics, Inc. (NASDAQ: IMMU) on 05/17/2011., when
the stock price was $3.85. Since then, Immunomedics, Inc. has lost 49.09% as of 01/07/2016's recent price of $1.96.
If you would have followed the previous Oppenheimer's recommendation on IMMU, you would have lost 49.09% of your investment in 1696 days.

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or `naked` form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/2/2013 8:25 AM Buy
6.98 8.00
as of 12/13/2013
1 Week down  -12.83 %
1 Month up  9.44 %
3 Months down  -34.98 %
1 YTD up  34.93 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/17/2011 8:25 AM Buy
3.85 6.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy